by Richard Daverman, PhD
April 20, 2013 -- Ascletis will collaborate with Roche to develop Roche’s hepatitis C virus drug in China; Thermo Fisher acquired Life Technologies, pitching the transaction as an attractive combination for Asian markets; the Zongyi Group of China invested $8.6 million in ContraFect Corporation, a New York biotech; Wuhan Kindstar Diagnostics, a testing service for China hospitals, will collaborate with Illumina; Cipla launched a biosimilar version of the arthritis treatment Enbrel in India, which it sources from Shanghai CP Guojian; Suzhou Ascepion Pharma said Debiopharm of Switzerland will support further China development of a cancer treatment; Eddingpharm and Chiesi Farmaceutici formed a JV to market two of Chiesi’s asthma drugs in China; Merck opened its new $120 million drug packaging facility in Hangzhou; Injex Pharma of Germany received SFDA approval to market its INJEX30 needle-free injection system in China for insulin; Shenzhen Chipscreen Biosciences’ lymphoma treatment met its primary endpoint in a Phase II trial; and a subsidiary of Inner Mongolia Furui Medical was given FDA 510(k) approval to market its liver fibrosis device in the US. More details….
Stock Symbols: (VX: ROG) (NYSE: TMO) (NSDQ: LIFE) (NSDQ: ILMN) (NYSE: MRK) (BSE: 500087) (SHE: 300049)
